Outcomes of Transcatheter Edge‐to‐Edge Repair in Potentially Favorable Candidates for Left Ventricular Assist Device: Evidence From the OCEAN‐Mitral Registry

Read full text Summarise with VIRAT
Authors: Shuhei Tanaka, Teruhiko Imamura, Yuki Hida, Ryuichi Ushijima, Nobuyuki Fukuda, Hiroshi Ueno, Koichiro Kinugawa, Masanori Yamamoto, Shunsuke Kubo, Yuki Izumi, Mike Saji, Masahiko Asami
+19 more Yusuke Enta, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Hisao Otsuki, Toru Naganuma, Hiroki Bota, Yohei Ohno, Masahiro Yamawaki, Gaku Nakazawa, Daisuke Hachinohe, Atsushi Sugiura, Tetsuro Shimura, Toshiaki Otsuka, Kentaro Hayashida, OCEAN‐Mitral investigators
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) has shown promising outcomes in patients with advanced heart failure and significant mitral regurgitation. Similarly, outcomes after left ventricular assist device (LVAD) implantation have improved in advanced heart failure with/without mitral regurgitation. However, the indication of M‐TEER in favorable candidates for LVAD therapy remains unclear. Methods Potentially favorable LVAD candidates were defined as patients with advanced heart failure and secondary mitral regurgitation who underwent M‐TEER and were considered theoretically suitable for LVAD therapy based on data from the optimized catheter valvular intervention (OCEAN)‐Mitral registry. Among this cohort, Cox proportional hazards regression analysis was performed to identify factors associated with cardiovascular death following M‐TEER. Results A total of 3764 patients who underwent M‐TEER were included. Of them, 129 were identified as potentially favorable LVAD candidates (mean age: 67 years; 67% men). Despite advanced heart failure, procedural success was 96%. The 1‐year rate of cardiovascular death was 10.1%, increasing to 38.9% at 3 years. Baseline left ventricular end‐diastolic diameter was independently associated with cardiovascular death (hazard ratio: 1.07 per 1‐mm increase; 95% CI: 1.02–1.12; P =0.01). In patients with markedly enlarged left ventricles, symptom improvement was limited, and reverse remodeling was not achieved. Conclusions M‐TEER can be safely performed even in potentially favorable LVAD candidates. However, long‐term efficacy appears limited, particularly in those with advanced LV remodeling. Further studies are warranted to establish an optimal strategy, including the role of LVAD therapy versus M‐TEER, for this high‐risk population. Registration URL: https://center6.umin.ac.jp/cgi‐open‐bin/ctr/ctr_view.cgi?recptno=R000027188 .

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Mechanical Circulatory Support Devices Cardiac Structural Anomalies and Repair

Publication details

Journal / source
Journal of the American Heart Association
Volume
15
Issue
7
Pages
e046638–e046638
Publication date
25 March 2026
Language
EN